With Organic Oxygen Containing Compound Patents (Class 514/164)
-
Publication number: 20120213717Abstract: In certain embodiments, the present invention is directed to the use of soothing agents to relieve mild irritation and/or enhance the overall soothing, comfort or refreshing feel of mucosal membranes of the eye, oral cavity, otic, nose, throat or vaginal area. The present invention further relates to compositions, articles and methods for masking or reducing the irritant properties of sensory compounds, such as terpenes and/or phenolic agents.Type: ApplicationFiled: February 18, 2011Publication date: August 23, 2012Applicant: McNeil-PPC, Inc.Inventor: Mandar V. Shah
-
Publication number: 20120201769Abstract: Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.Type: ApplicationFiled: February 2, 2012Publication date: August 9, 2012Applicant: Unigen, Inc.Inventors: Mei Feng Hong, Qi Jia, Lidia Alfaro Brownell
-
Publication number: 20120189684Abstract: This invention relates to skincare compositions, in particular compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin that involve the application of such compositions, wherein the compositions comprise salicylic acid or a salt thereof in combination with at 2 actives selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; bisabolol; cetylhydroxyproline palmitamide; allantoin; niacinamide; and epilobium angustifolium extract.Type: ApplicationFiled: July 19, 2010Publication date: July 26, 2012Applicant: Reckitt Benckiser Healthcare International LimitedInventors: Carolyn Buckley, Stuart Jackson, Neil Kilcullen, Diane Marie Pavis
-
Publication number: 20120184513Abstract: The invention relates to organic compounds having the ability to reduce or suppress the onset of skin irritation induced by extraneous cause selected from the group of 2-heptylcyclopentanone, 2-ethoxynaphthalene; 2-methoxynaphthalene; 1-methoxy-4-(prop-1-enyl)benzene; 1-(cyclopropylmethyl)-4-methoxybenzene; wherein X, Y, and R1 to R11 have the same meaning as given in the description. Furthermore the invention refers to compositions for topical application to the skin comprising them. It further relates to a method of reducing or suppressing the formation of skin irritation.Type: ApplicationFiled: January 14, 2011Publication date: July 19, 2012Applicant: Givaudan SAInventors: Andreas NATSCH, Michael WASESCHA
-
Patent number: 8211876Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: December 24, 2009Date of Patent: July 3, 2012Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty
-
Patent number: 8211878Abstract: The present invention provides methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death in a patient. The invention includes use of 5-benzylamino salicylic acid (BAS) and its derivatives. Thus, the present invention provides methods for reducing neuronal death in nervous system injuries resulting from amyotrophic lateral sclerosis.Type: GrantFiled: May 24, 2010Date of Patent: July 3, 2012Assignee: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung Joo Gwag, Young Ae Lee, Bo Rum Ryu, Sung Hwa Yoon, Ho Sang Moon
-
Publication number: 20120165299Abstract: A medicament for treating inflammation of human or animal body tissues contains a steroid, typically a corticosteroid, in combination with a non-steroidal anti-inflammatory drug (NSAID), typically a cyclooxygenase (COX-1 or COX-2) inhibitor. The medicament is of a particular effectiveness in treating inflammation of and around the eyes, whether caused by infection, irritation or surgery. Further medicaments combine an NSAID with antihistamines or with mast cell stabilisers. The medicaments are particularly effective in topically-applicable form, although other forms of application should also show benefits.Type: ApplicationFiled: September 3, 2010Publication date: June 28, 2012Inventor: Anant Sharma
-
Publication number: 20120164193Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: March 19, 2012Publication date: June 28, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Patent number: 8207148Abstract: The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts and antimicrobial agents in coatings for medical articles. The coatings have an anti-irritant effect and inhibit transmission of infectious disease.Type: GrantFiled: March 1, 2010Date of Patent: June 26, 2012Assignee: The Trustees of Columbia University in the City of New YorkInventors: Shanta M. Modak, Lauserpina Caraos
-
Publication number: 20120156146Abstract: A method of improving the appearance of facial texture may comprise the step of applying a composition comprising an effective amount of a material that regulates hyaluronic acid synthesis to an area of textured facial skin, wherein the composition is applied for a period of time sufficient for the material to improve the appearance of the facial texture. In some embodiments, the material that regulates hyaluronic acid synthesis is hexyldecanol. The method may also include the step of identifying facial texture on a facial skin surface. In particular embodiments, the facial skin texture is selected from the group consisting of macro-texture, micro-texture, and combinations thereof.Type: ApplicationFiled: November 17, 2011Publication date: June 21, 2012Inventors: Tomohiro HAKOZAKI, Leo Timothy Laughlin, II
-
Publication number: 20120149667Abstract: A stable and/or synergistic pharmaceutical composition including: a) predinisolone metasulfobenzoate (PMSB) or its acceptable salts, preferably prednisolone metasulfobenzoate sodium and b) 5-ASA, derivatives or pharmaceutically acceptable salts thereof, which is suitable for rectal administration.Type: ApplicationFiled: August 25, 2010Publication date: June 14, 2012Applicants: DISPHAR INTERNATIONAL BV, NORDIC PHARMAInventors: Hans Schram, Michael Ikechukwu Ugwoke, Laura Buttafoco
-
Publication number: 20120148510Abstract: A method of improving the appearance of facial pores is provided. The method includes the step of applying a composition having an effective amount of a material that regulates IL-1 and/or hyaluronic acid synthesis to an area of facial pores, wherein the composition is applied for a period of time sufficient for the material to improve the appearance of the facial pores. In some embodiments, the material that regulates IL-1 and/or hyaluronic acid synthesis is hexyldecanol. The method may also include the step of identifying facial pores on a facial skin surface.Type: ApplicationFiled: November 17, 2011Publication date: June 14, 2012Inventors: Tomohiro HAKOZAKI, Leo Timothy Laughlin, II
-
Publication number: 20120141554Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: January 4, 2012Publication date: June 7, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120135050Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: January 4, 2012Publication date: May 31, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. DILL
-
Publication number: 20120128793Abstract: Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device.Type: ApplicationFiled: January 24, 2012Publication date: May 24, 2012Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Kathleen M. Miller, Gregory T. Sydney, Kurt Geitz, Peter L. Dayton, Ronald A. Sahatjian
-
Publication number: 20120121665Abstract: Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device.Type: ApplicationFiled: January 24, 2012Publication date: May 17, 2012Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Kathleen M. Miller, Gregory T. Sydney, Kurt Geitz, Peter L. Dayton, Ronald A. Sahatjian
-
Publication number: 20120107400Abstract: A pH dependent drug delivery system comprising a pH sensitive graft copolymer, a therapeutically active agent and other pharmaceutically acceptable ingredients. More specifically, a composition which is capable of suppressing the drug release in the acidic pH prevalent in the stomach and releasing the drug over an extended period of time at pH prevalent in the intestinal region.Type: ApplicationFiled: March 5, 2010Publication date: May 3, 2012Inventors: Ramesh Muthusamy, Mohan Gopalkrishna Kulkarni
-
Publication number: 20120093952Abstract: The present invention relates to the use of essential oil compounds as histomonastats. An example of a essential oil compound of the invention is cinnamaldehyde.Type: ApplicationFiled: November 20, 2008Publication date: April 19, 2012Inventors: Marco Frehner, Riccardo Losa, Didier Archain
-
Publication number: 20120094965Abstract: A chemical peeling formulation and a formulation able to increase the efficacy and the tolerability of preparations based on the use of compounds used to carry out chemical peeling, comprising at least one keratolytic agent and dimethyl isosorbide. The composition may additionally comprise dimethyl sulphone.Type: ApplicationFiled: April 19, 2011Publication date: April 19, 2012Inventor: Gianfranco de Paoli Ambrosi
-
Publication number: 20120087947Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.Type: ApplicationFiled: August 15, 2011Publication date: April 12, 2012Applicant: AmDerma Pharmaceuticals, LLCInventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20120077785Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.Type: ApplicationFiled: September 13, 2011Publication date: March 29, 2012Applicant: Action MedicinesInventors: Pedro Cuevas Sanchez, Antonio Romero Garrido, Guillermo Gimenez Gallego, SerafÃn Valverde Lopez, Rosa MarÃa Lozano Puerto
-
Publication number: 20120064149Abstract: The present invention relates to hexylresorcinol/water concentrates that are high in clarity, easily handled, and readily blended with other ingredients to form skin care compositions.Type: ApplicationFiled: November 17, 2011Publication date: March 15, 2012Inventors: Kalonda Tymika Johnson, John Lemmo, Michael Southall, Ping Wen
-
Patent number: 8119618Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: March 11, 2009Date of Patent: February 21, 2012Assignee: The Board of Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20120034312Abstract: This invention relates to the use of 4-isopropyl-3-methylphenol (IPMP) for combating inflammation and compositions comprising IPMP for such use.Type: ApplicationFiled: April 1, 2010Publication date: February 9, 2012Inventor: Jingjun Yang
-
Publication number: 20120022029Abstract: A topical pain reliever and method of making the same is disclosed. The topical pain reliever may comprise effective amounts of water, glycerine, analgesic agent such as salicylic acid or a derivative thereof, and alcohol. The method of making the topical pain reliever may maintain the analgesic agent in suspension within a solution. The topical pain reliever may be applied to the skin of a user to provide pain relief without ingestion of the composition, thereby potentially avoiding adverse side effects.Type: ApplicationFiled: July 26, 2011Publication date: January 26, 2012Inventors: James M. Berling, Gene A. Tabish, Marion Louise Berling
-
Publication number: 20120015912Abstract: The present invention relates to the use of a compound of Formula (IIV) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of any of the diseases selected from the group consisting of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy.Type: ApplicationFiled: January 7, 2011Publication date: January 19, 2012Applicant: Action MedicinesInventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Maria Luisa Krauel, Javier Angulo Frutos, Rosa Maria Lozano Puerto, Antonio Romero Garrido, Serafin Valverde Lopez
-
Patent number: 8066976Abstract: The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterised in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating agent.Type: GrantFiled: March 16, 2010Date of Patent: November 29, 2011Assignee: Galderma S.A.Inventors: Isabelle Preuilh, Anne-Emmanuelle Guise, Nathalie Willcox
-
Patent number: 8066975Abstract: The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterized in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating agent.Type: GrantFiled: November 13, 2007Date of Patent: November 29, 2011Assignee: Galderma S.A.Inventors: Isabelle Preuilh, Anne-Emmanuelle Guise, Nathalie Willcox
-
Publication number: 20110212196Abstract: A therapeutic composition having at least one botanical active ingredient, carvone, derived from plants such as mint Mentha sp., caraway Carum carvi or dill Anethum graveolens. Carvone is capable of anesthetizing teleost, elasmobranch, and agnathan fishes as well as amphibians by contact with skin and/or gills. Carvone has two natural enantiomers; both have anesthetic properties on these fishes and amphibians. Carvone in combinations with other sodium channel blockers such as methyl salicylate have a synergistic effect and are more efficient at anesthetizing teleosts, elasmobranchs and agnathan fishes than carvone alone. This invention has value because it offers an opportunity to forumulate fish anesthetizing drugs with a compound that is also documented to be safe for human consumption.Type: ApplicationFiled: March 1, 2010Publication date: September 1, 2011Applicant: MAINE CONSERVATION MEDICINE CENTERInventor: G. Russell Danner
-
Publication number: 20110196383Abstract: A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in a patient's blood vessels is provided. A chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive substance is administered at sites of the plaques. The chemical composition comprises one or more of d-limonene, propylene glycol, octanoic acid, 2-octane, glycerine, acetylsalicylic acid, acetic acid, omega-3 fatty acids, ethanol, methanol, ezetimibe, rosuvastatin, resveratrol, lactic acid, gluconic acid, chloroform, carbon disulfide, dichloromethane, toluene, lauryldimethyl hydroxysultaine, and any combination thereof. The chemical composition enables modification of plaques by altering their composition. The modification comprises partial dissolution, complete dissolution, or elimination of the plaques, and makes the plaques amenable to different forms of plaque treatment. The modified plaques are eliminated from the patient's body.Type: ApplicationFiled: April 15, 2011Publication date: August 11, 2011Inventors: Kusai Saadeldin Aziz, Gary Michael Saxton
-
Publication number: 20110189249Abstract: A low pH composition containing a retinol and a method for treating skin is disclosed. The composition contains (a) a retinoid and (b) an active acid, like an alpha-hydroxy acid or a beta-hydroxy acid, and has a pH of less than 5.Type: ApplicationFiled: September 9, 2009Publication date: August 4, 2011Applicant: AMCOL INTERNATIONAL CORPORATIONInventors: Limin Liu, Ralph Spindler, Gholam-Reza Vakili-Tahami
-
Publication number: 20110183011Abstract: Disclosed herein is a composition containing a high concentration of PG is unexpectedly capable of quickly killing other bacteria, fungi, and/or virus in vitro that is indicative of its potential high efficacy in treating various skin infection. Embodiments disclosed herein relate to a composition and method for effective topical treatment of inflammatory skin lesions in mammals, comprising of a high concentration of propylene glycol alone, or in combination with an astringent. The PG at high concentrations can be regarded as an extremely effective, safe, topical, universal, microbicide.Type: ApplicationFiled: April 5, 2011Publication date: July 28, 2011Applicant: WINLIND SKINCARE LLCInventor: WIN L. CHIOU
-
Patent number: 7985743Abstract: A topical pain reliever and method of making the same is disclosed. The topical pain reliever may comprise effective amounts of water, glycerine, analgesic agent such as salicylic acid or a derivative thereof, and alcohol. The method of making the topical pain reliever may maintain the analgesic agent in suspension within a solution. The topical pain reliever may be applied to the skin of a user to provide pain relief without ingestion of the composition, thereby potentially avoiding adverse side effects.Type: GrantFiled: July 21, 2006Date of Patent: July 26, 2011Inventors: James M. Berling, Marion Louise Berling, legal representative, Gene A. Tabish
-
Publication number: 20110142769Abstract: An active agent delivery composition is provided that allows topical delivery of active agents including vitamin A and its derivatives. A polyhalogenic vehicle such as methoxyonafluorobutane or ethoxyonafluorobutane serves as a coupler for an active agent and a silicone carrier so as to allow solubilization of active agents not normally miscible in silicones and providing a moisture maintaining composition.Type: ApplicationFiled: February 24, 2010Publication date: June 16, 2011Inventor: John E. Kulesza
-
Publication number: 20110130704Abstract: The present invention relates to a cosmetic method intended in particular to improve the appearance of the skin and/or hair comprising the simultaneous and/or sequential administration: a) of at least one compound bioconvertible by lipase; and b) of at least one light radiation exhibiting at least one predominant wavelength which activates lipase. In particular, the said light radiation according to the invention exhibits (emits) at least one predominant wavelength which activates lipase ranging from 400 to 510 nm, preferably from 430 to 500 nm, and is preferably used at a dose ranging from 0.01 to 200 J/cm2, preferably from 0.1 to 30 J/cm2, more preferably from 1 to 30 J/cm2, indeed even from 5 to 30 J/cm2.Type: ApplicationFiled: February 25, 2009Publication date: June 2, 2011Applicant: L'OREALInventors: Francine Baldo, Quang Lan Nguyen, Dang-Man Pham
-
Patent number: 7928092Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: GrantFiled: June 10, 2010Date of Patent: April 19, 2011Assignee: AGI Therapeutics Ltd.Inventors: John Devane, Jackie Butler
-
Publication number: 20110086823Abstract: The invention relates to a disinfectant which comprises a special combination of biocidal phenols and, where appropriate, phenol derivatives and a keratolytic. The disinfectant is particularly suitable for controlling parasitic protozoa including their persistent forms.Type: ApplicationFiled: December 17, 2010Publication date: April 14, 2011Applicants: BAYER ANIMAL HEALTH GMBH, LANXESS DEUTSCHLAND GMBHInventors: Gisela GREIF, Robrecht FROYMAN, Claudio ORTIZ, Gerd-Friedrich RENNER, Otto EXNER, Dietmar SCHLEGEL, Rolf MATYSIAK
-
Patent number: 7893106Abstract: Disclosed are novel oxylipins that are derived from ?-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.Type: GrantFiled: January 31, 2007Date of Patent: February 22, 2011Assignee: Martek Biosciences, CorporationInventors: Linda Mary Arterburn, William Barclay, Bindi Dangi, James Flatt, Jung Lee, Dutt Vinjamoori
-
Publication number: 20110015134Abstract: This patent describes a method and materials to treat cancer diagnosed at an early stage, particularly breast cancer. It considers that metastatic breast cancer growth includes periods of dormancy, that surgery to remove a primary tumor can induce metastatic growth, and that women with Down Syndrome rarely get breast cancer. It elevates the level of an antiangiogenic drug produced by chromosome 21 preferably Endostatin in plasma preferably at least one day prior to surgery and kept at that high level preferably indefinitely. In one embodiment, the therapy specifically excludes drugs that significantly inhibit the VEGF pathway since that is important for wound healing. This method will prevent results of surgery from stimulating tumor growth and angiogenesis of micrometastatic disease that is much easier to prevent than control after the fact. This can be done indefinitely since there is no acquired resistance that develops, as happens in most cancer therapies.Type: ApplicationFiled: September 22, 2010Publication date: January 20, 2011Inventor: Michael W. Retsky
-
Publication number: 20100330011Abstract: Silicone organic gels and gel paste compositions are disclosed containing a silicone organic elastomer in a carrier fluid. The silicone organic elastomer is a reaction product of a linear or branched organohydrogensiloxane, an ?, ?-unsaturated polyoxyalkylene, and a hydrosilylation catalyst. The silicone organic elastomer is particularly useful to ge! organic earner fluids, The gels and gels pastes also provide enhanced compatibility with many personal and health care actives.Type: ApplicationFiled: June 24, 2008Publication date: December 30, 2010Inventors: John Joseph Kennan, Kathryn Elizabeth Messner
-
Publication number: 20100323996Abstract: The present invention relates to a cosmetic composition for the cleaning of the skin, said composition comprising or consisting of one or more compounds of formula (I) wherein represents a single bond or double bond; R1 and R2 are independently selected from H, linear or branched C1 to C4 alkyl, linear or branched C1 to C4 alkenyl, linear or branched C1 to C4 alkinyl, and linear or branched C1 to C4 alkanoyl; R4 is selected from H, linear or branched C1 to C4 alkyl, linear or branched C1 to C4 alkenyl, and linear or branched C1 to C4 alkinyl; and R3 and R5 are independently selected from H, OH and halogen, or R3 and R5 together are O to form an epoxid, wherein represents a single bond in case R3 and R5 together are O. Also provided are means and methods for the prevention or reduction of biofilm formation on an intracorporeal device and/or for the removal of biofilm from an intracorporeal device, wherein said biofilm comprises or consists of bacteria of the genus Propionibacterium.Type: ApplicationFiled: February 18, 2009Publication date: December 23, 2010Applicant: Biotechnology Research and Information Network (B.R.A.I.N.)Inventors: Dechert Ute, Eck Jurgen, Krohn Michael
-
Publication number: 20100311700Abstract: A transdermal preparation for external use which contains a photosensitive NSAID and a UV blocker having a high ability to migrate into the skin. Thus, it becomes possible to ensure, in a transdermal preparation for external use containing a NSAID, the inhibition of the onset of light-induced non-immunological or immunological skin symptoms by the above-described component.Type: ApplicationFiled: April 29, 2010Publication date: December 9, 2010Applicant: Hisamitsu Pharmaceutical Co., Inc.Inventors: Kazuhisa Yoshitake, Kenji Atarashi, Tetsuji Kuwahara, Koichi Ikesue, Michinori Sakai, Yoshiaki Hashimoto, Kiyomi Tsuruda
-
Publication number: 20100278917Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: ApplicationFiled: June 10, 2010Publication date: November 4, 2010Inventors: John Devane, Jackie Butler
-
Patent number: 7825106Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: GrantFiled: March 10, 2006Date of Patent: November 2, 2010Assignee: AGI Therapeutics Ltd.Inventors: John Devane, Jackie Butler
-
Publication number: 20100239552Abstract: This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier.Type: ApplicationFiled: March 16, 2010Publication date: September 23, 2010Applicant: GENMEDICA THERAPEUTICS SLInventors: Eric Mayoux, Luc Marti Clauzel, Silvia Garcia-Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Alec Mian
-
Patent number: 7786100Abstract: A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is greater than the effect of the individual components alone. The composition includes a biologically effective amount of vitamin E for inhibiting propagation of lipid peroxidation that contributes to hearing loss. The composition also includes a biologically effective amount of a salicylate for reducing hydroxyl radicals that contribute to hearing loss. A method of treating hearing loss includes the step of internally administering the composition, as described above, to a mammal within three days of trauma to a middle or inner ear of the mammal. In other words, the composition is effective even when administered as late as three days after trauma to a middle or inner ear of a mammal.Type: GrantFiled: March 20, 2006Date of Patent: August 31, 2010Assignee: The Regents of the University of MichiganInventors: Josef Miller, Colleen Garbe-LePrell, Daisuke Yamashita
-
Publication number: 20100216749Abstract: The present invention relates to combination therapy of a pyruvoyl derivative and an anti-oxidant, which is characterized by significant increase of the activity of microglia, inhibition of brain tissue damage by the activation of inflammatory cytokines, improvement of motor skill and recovery effect of neuronal damage. Compared to single treatment with each, this present invention provides a continuous high neuroprotective effect even after 6 hours from the onset of damage.Type: ApplicationFiled: October 3, 2008Publication date: August 26, 2010Applicant: S.H. PHARMA., LTDInventors: Sung-Hwa Yoon, Ja-Kyeong Lee, Ho-Joon Park, Young-Gyun Shin, Hae-Un Lee, Seung-Woo Kim, Hyun-Ji Kim
-
Publication number: 20100189669Abstract: Personal care compositions containing an active selected from the group consisting of phlorogine, phlorgine BG, deoxyArbutin, sucrose dilaurate, bakuchiol, pyrenoine, millet, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid, zinc undecylenate, L-tryptophan, thiamine HCl, hexylresorcinol, lipidami red vine, dragosine, methyl gentisate, inositol, symdiol 68, laminaine, their salts, their derivatives, their precursors, and/or combinations thereof. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.Type: ApplicationFiled: January 25, 2010Publication date: July 29, 2010Inventor: Tomohiro Hakozaki
-
Publication number: 20100183519Abstract: This invention relates to therapeutic compositions comprising a surface active copolymer, such as poloxamer-188, in an amount effective to enhance microvascular blood flow and/or inflammation in injured skin or other tissue, and methods of using the therapeutic compositions of the invention to inhibit decreased blood flow associated with an injury, disease, or disorder.Type: ApplicationFiled: June 6, 2008Publication date: July 22, 2010Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Adam J. Katz, George T. Rodeheaver
-
Publication number: 20100158828Abstract: Cosmetic compositions comprising cis-6-nonenol and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. Cis-6-nonenol is believed to have modulatory activity against at least one biochemical pathway implicated in skin aging.Type: ApplicationFiled: December 23, 2008Publication date: June 24, 2010Applicant: Avon Products, Inc.Inventors: Dmitri S. Ptchelintsev, Cheng Shine Hwang